Entity Details

Primary name FAAA_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP16930
EntryNameFAAA_HUMAN
FullNameFumarylacetoacetase
TaxID9606
Evidenceevidence at protein level
Length419
SequenceStatuscomplete
DateCreated1990-08-01
DateModified2021-06-02

Ontological Relatives

GenesFAH

GO terms

Show/Hide Table
GOName
GO:0004334 fumarylacetoacetase activity
GO:0005829 cytosol
GO:0006527 arginine catabolic process
GO:0006559 L-phenylalanine catabolic process
GO:0006572 tyrosine catabolic process
GO:0046872 metal ion binding
GO:0070062 extracellular exosome
GO:1902000 homogentisate catabolic process

Subcellular Location

Show/Hide Table

Domains

Show/Hide Table
DomainNameCategoryType
IPR005959 FumarylacetoacetaseFamilyFamily
IPR011234 Fumarylacetoacetase-like, C-terminalDomainDomain
IPR015377 Fumarylacetoacetase, N-terminalDomainDomain
IPR036462 Fumarylacetoacetase, N-terminal domain superfamilyFamilyHomologous superfamily
IPR036663 Fumarylacetoacetase-like, C-terminal domain superfamilyFamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
276700 OMIMTyrosinemia 1 (TYRSN1)An inborn error of metabolism characterized by elevations of tyrosine in the blood and urine, and hepatorenal manifestations. Typical features include hepatic necrosis, renal tubular injury, episodic weakness, self-mutilation, and seizures. Renal tubular dysfunction is associated with phosphate loss and hypophosphataemic rickets. Progressive liver disease can lead to the development of hepatocellular carcinoma. Dietary treatment with restriction of tyrosine and phenylalanine alleviates the rickets, but liver transplantation has so far been the only definite treatment. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB01677 Fumaric AcidDrugbanksmall molecule
DB01762 Acetoacetic acidDrugbanksmall molecule
DB01832 4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic AcidDrugbanksmall molecule